Q2 2024 |
|
|
|
|
|
|
13F-NT |
8/9/2024, 04:47 PM |
Q1 2024 |
|
|
|
|
|
|
13F-NT |
5/3/2024, 04:39 PM |
Q4 2023 |
0 |
|
|
|
|
|
13F-NT |
2/2/2024, 04:47 PM |
Q3 2023 |
0 |
|
|
|
|
|
13F-NT |
11/3/2023, 04:44 PM |
Q2 2023 |
0 |
|
|
|
|
|
13F-NT |
8/4/2023, 04:41 PM |
Q1 2023 |
0 |
|
|
|
|
|
13F-NT |
5/5/2023, 05:01 PM |
Q4 2022 |
19 |
$304M |
$0 |
-$103M |
-$103M |
PCVX, VRNA, VERA, HLVX, ACET
|
13F-HR |
2/10/2023, 04:28 PM |
Q3 2022 |
19 |
$292M |
+$4.92M |
-$79.2M |
-$74.2M |
PCVX, VERA, HLVX, ACET, VRNA
|
13F-HR |
11/10/2022, 04:48 PM |
Q2 2022 |
21 |
$312M |
+$19.9M |
-$14.7M |
+$5.25M |
PCVX, SRRA, VERA, ACET, HLVX
|
13F-HR |
8/15/2022, 06:30 AM |
Q1 2022 |
20 |
$352M |
+$18.9M |
$0 |
+$18.9M |
PCVX, VERA, ACET, SRRA, JSPR
|
13F-HR |
5/16/2022, 07:00 AM |
Q4 2021 |
20 |
$413M |
+$8.72M |
$0 |
+$8.72M |
PCVX, VERA, JSPR, EFTR, ACET
|
13F-HR |
2/16/2022, 11:26 AM |
Q3 2021 |
20 |
$441M |
+$126M |
-$1.73M |
+$124M |
PCVX, EFTR, JSPR, VERA, PHAT
|
13F-HR |
11/15/2021, 06:05 AM |
Q2 2021 |
19 |
$324M |
+$56.7M |
$0 |
+$56.7M |
PCVX, PHAT, VERA, SIEN, RPHM
|
13F-HR |
8/16/2021, 06:30 AM |
Q1 2021 |
17 |
$290M |
+$22.9M |
$0 |
+$22.9M |
PCVX, PHAT, ACET, VRNA, SIEN
|
13F-HR |
5/17/2021, 06:11 AM |
Q4 2020 |
15 |
$292M |
+$43.1M |
-$119M |
-$75.7M |
PCVX, PHAT, SLNO, VRNA, NCNA
|
13F-HR |
3/1/2021, 11:18 AM |
Q3 2020 |
17 |
$468M |
+$27.3M |
-$43.1M |
-$15.8M |
PCVX, PSNL, PHAT, SLNO, CRSP
|
13F-HR |
11/16/2020, 06:15 AM |
Q2 2020 |
16 |
$355M |
+$139M |
-$3.97M |
+$135M |
PCVX, PSNL, PHAT, CRSP, SLNO
|
13F-HR |
8/14/2020, 03:27 PM |
Q1 2020 |
16 |
$151M |
+$9.09M |
-$879K |
+$8.21M |
PSNL, PHAT, CRSP, SLNO, XCUR
|
13F-HR |
5/14/2020, 06:05 AM |
Q4 2019 |
16 |
$207M |
+$48.9M |
-$6.65M |
+$42.3M |
PSNL, PHAT, CRSP, SIEN, SLNO
|
13F-HR |
2/14/2020, 06:05 AM |
Q3 2019 |
14 |
$158M |
+$15.8M |
-$38M |
-$22.3M |
PSNL, CRSP, XCUR, SIEN, SLNO
|
13F-HR |
11/14/2019, 06:06 AM |
Q2 2019 |
14 |
$261M |
+$148M |
-$13.8M |
+$134M |
PSNL, CRSP, SIEN, AVDR, SLNO
|
13F-HR |
8/14/2019, 06:09 AM |
Q1 2019 |
14 |
$112M |
+$13.4M |
-$12.5M |
+$856K |
CRSP, SIEN, CHMA, SLNO, AVDR
|
13F-HR |
5/15/2019, 06:15 AM |
Q4 2018 |
16 |
$110M |
+$7.98M |
-$4.32M |
+$3.67M |
CRSP, SIEN, VRNA, SLNO, CHMA
|
13F-HR |
2/14/2019, 06:16 AM |
Q3 2018 |
16 |
$168M |
+$11.3M |
-$11.9M |
-$644K |
CRSP, SIEN, VRNA, PRTK, OBSVF
|
13F-HR |
11/14/2018, 06:15 AM |
Q2 2018 |
16 |
$175M |
+$7.22M |
-$38.8M |
-$31.5M |
CRSP, SIEN, PRTK, OBSVF, GTXI
|
13F-HR |
8/14/2018, 07:00 AM |
Q1 2018 |
16 |
$161M |
+$2.98M |
-$18.1M |
-$15.1M |
CRSP, SIEN, PRTK, GTXI, OBSVF
|
13F-HR |
5/15/2018, 06:08 AM |
Q4 2017 |
17 |
$138M |
$0 |
-$4.44M |
-$4.44M |
CRSP, SIEN, PRTK, CBAY, OBSVF
|
13F-HR |
2/14/2018, 06:10 AM |
Q3 2017 |
18 |
$144M |
+$8.61M |
-$16.8M |
-$8.22M |
CRSP, SIEN, PRTK, CBAY, CHMA
|
13F-HR |
11/14/2017, 06:13 AM |
Q2 2017 |
16 |
$126M |
$0 |
-$3.45M |
-$3.45M |
CRSP, PRTK, SIEN, CBAY, CASC
|
13F-HR |
8/14/2017, 06:02 AM |
Q1 2017 |
17 |
$134M |
+$6.72M |
-$2.18M |
+$4.54M |
CRSP, PRTK, SIEN, CBAY, CASC
|
13F-HR |
5/15/2017, 07:36 AM |
Q4 2016 |
18 |
$119M |
+$53.2M |
-$13.7M |
+$39.4M |
CRSP, PRTK, SIEN, NOVN, CHMA
|
13F-HR |
2/14/2017, 06:04 AM |
Q3 2016 |
20 |
$104M |
+$4.8M |
-$7.61M |
-$2.82M |
SIEN, PRTO, PRTK, CEMP, CHMA
|
13F-HR |
11/14/2016, 07:20 AM |
Q2 2016 |
20 |
$95.5M |
+$4.78M |
-$533K |
+$4.25M |
PRTK, PRTO, SIEN, TBRA, CEMP
|
13F-HR |
8/12/2016, 06:03 AM |
Q1 2016 |
19 |
$108M |
+$256K |
$0 |
+$256K |
PRTK, CHMA, PRTO, SIEN, CEMP
|
13F-HR |
5/13/2016, 06:16 AM |
Q4 2015 |
18 |
$166M |
+$6.11M |
-$369K |
+$5.74M |
CHMA, PRTO, PRTK, SIEN, CEMP
|
13F-HR |
2/16/2016, 07:22 AM |
Q3 2015 |
17 |
$171M |
+$46.1M |
-$21.1M |
+$25M |
CHMA, PRTO, PRTK, SIEN, EVAR
|
13F-HR |
11/13/2015, 06:49 AM |
Q2 2015 |
16 |
$216M |
+$19M |
-$47.5M |
-$28.6M |
SIEN, PRTO, PRTK, AMRN, EVAR
|
13F-HR |
8/14/2015, 06:47 AM |
Q1 2015 |
17 |
$235M |
+$1.02M |
-$157M |
-$156M |
SIEN, PRTK, SUPN, DRNA, PRTO
|
13F-HR |
5/14/2015, 06:03 AM |
Q4 2014 |
16 |
$352M |
+$108M |
-$56K |
+$108M |
RNA, PRTK, SIEN, PTLA, SUPN
|
13F-HR |
2/13/2015, 06:12 AM |
Q3 2014 |
13 |
$167M |
+$25.7M |
-$14.2M |
+$11.5M |
RNA, EVAR, SUPN, PTLA, DRNA
|
Restatement |
11/25/2014, 03:07 PM |
Q2 2014 |
12 |
$215M |
+$1.58M |
-$7.63M |
-$6.05M |
RNA, SUPN, PTLA, DRNA, AMRN
|
13F-HR |
8/14/2014, 06:53 AM |
Q1 2014 |
13 |
$181M |
+$36.3M |
$0 |
+$36.3M |
RNA, DRNA, SUPN, PTLA, AMRN
|
13F-HR |
5/20/2014, 06:33 PM |
Q4 2013 |
11 |
$133M |
$0 |
$0 |
|
PTLA, RNA, SUPN, AMRN, CEMP
|
13F-HR |
2/14/2014, 08:47 AM |